Wen Hong Lin

Wen Hong Lin has worked in the clinical research field since 2001, beginning as a CRA at PPD. From 2006 to 2007, they were a Project Manager at Advanced Biologics, and a Senior Early Clinical Scientist at Schering-Plough Research Institute from 2007 to 2009. Wen Hong then moved to Merck as an Associate Principal Scientist from 2009 to 2014. After that, they were an Expert Clinical Manager at Novartis Oncology from 2014 to 2015, and a Sr. Clinical Research Scientist at Pearl Therapeutics from 2015 to 2016. From 2016 to 2019, they were a Medical Director at Bristol-Myers Squibb, and a Senior Medical Director at Bristol Myers Squibb from 2019 to 2021. Currently, they are a Global Clinical Program Lead at Genmab, and will become Vice President Clinical Development at Immune-Onc Therapeutics in 2022.

Wen Hong Lin has completed a Master's degree in Pharmacology from The University of British Columbia and a Doctor of Medicine (MD) from Jinan University in the field of Medicine.